Trastuzumab deruxtecan (T-DXd)

优赫得 (Enhertu)

AstraZeneca/Daiichi Sankyo · Class: HER2 ADC

An antibody-drug conjugate: a HER2 antibody carrying a chemo payload straight into cancer cells. One of the most effective breast-cancer drugs ever tested.

At a glance

China price
Verified pricing is not currently available.
NRDL (national insurance)
Entered NRDL in a recent adjustment (partial indications).
Regulatory status
NMPA approved (2023)
International comparison
US list ~USD 2,500+ per 100mg

What it treats

HER2-positive and HER2-low breast cancer after prior therapy; HER2+ gastric cancer.

How it is accessed in China

← All drugs

Sources & verification

Overall status: Pending verification.

No independent source is currently on file. We have not independently verified this information.

Reader discussion

Public comments about Trastuzumab deruxtecan (T-DXd). Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.